Notice of Annual General Meeting
The Annual General Meeting of Targovax ASA (the "Company") will be held at the Company’s offices at Lysaker, on 29 April 2020 at 13:00 CET.
As a consequence of the extraordinary situation related to the corona virus the Company encourages shareholders not to attend the general meeting in person, but rather to make use of the ability to cast an advance vote or to vote by proxy.
The Company will hold the general meeting in such a way as to minimize the risk of infection as much as possible and will take such measures as may be necessary to comply with governmental regulations in connection with the general meeting.
The Annual General Meeting will be conducted as briefly as possible, and representation of Targovax's Board of Directors and administration will be kept to a minimum.
No refreshments will be served and necessary infection prevention measures will be taken for shareholders attending in person.
Notice of attendance
Notice of attendance must be received no later than 27 April 2020 at 16:00 CET. Casting of advance votes and submission of proxies must be received no later than 27 April 2020 at 16:00 CET. Attached you will find the notice to the General Meeting, including appendices. The notice and appendices will also be made available on Targovax’ website https://www.targovax.com/en/section/governance/general-meetings/.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Activating the patient's immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors. Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer.
ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal malignancies and has already shown promising clinical results both as monotherapy and in combination with chemotherapy, and a checkpoint inhibitor.